Bicara Therapeutics Inc. (BCAX): who owns it and who trades it
As of Nov 16, 2026, BCAX insiders reported 57 open-market sales worth $9.9M and 1 purchase worth $4.8M in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Ryan Cohlhepp (President), with $3.5M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Bicara Therapeutics
From the latest filingsOverall: more buying than selling. Funds, insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns BCAX
172 funds and institutions reported BCAX shares worth $2.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Ra Capital Management, L.P. with 11.1%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 7.26M | 11.08% | $215M | No change |
| T. Rowe Price Investment Management, Inc. | 6.34M | 9.68% | $188M | -4% |
| Siren, L.L.C. | 5.60M | 8.56% | $166M | -3% |
| Vestal Point Capital, LP | 5.25M | 8.02% | $156M | -3% |
| Deep Track Capital, LP | 4.10M | 6.26% | $122M | +1% |
| BlackRock, Inc. | 3.85M | 5.88% | $114M | +35% |
| Jupiter Topco LLC | 3.17M | 4.84% | $94M | – |
| Red Tree Management, LLC | 3.16M | 4.83% | $93.9M | -0% |
| Tpg Gp A, LLC | 3.01M | 4.60% | $89.4M | No change |
| Vanguard Capital Management LLC | 2.22M | 3.39% | $65.8M | +25% |
| State Street Corp | 2.05M | 3.13% | $60.8M | +44% |
| Franklin Resources Inc | 1.95M | 2.98% | $58M | +20% |
| T. Rowe Price Associates | 1.90M | 2.91% | $56.5M | +38% |
| FMR LLC (Fidelity) | 1.89M | 2.89% | $56.2M | -10% |
| Omega Fund Management, LLC | 1.82M | 2.78% | $54.1M | -24% |
| Geode Capital Management, LLC | 1.16M | 1.78% | $34.5M | +40% |
| California State Teachers Retirement System | 1.16M | 1.77% | $39M | +6742% |
| JPMorgan Chase & Co | 1.02M | 1.55% | $29.8M | – |
| Jones Hill Capital LP | 892,621 | 1.36% | $26.5M | -29% |
| Acorn Capital Advisors, LLC | 643,381 | 0.98% | $19.1M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, BCAX insiders reported $4.8M of open-market purchases and $9.9M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Ryan Cohlhepp | CEO | Sale plan | 3,442 | $23.43 | $80.6K | Form 4 |
| Sep 8, 2026 | Ryan Cohlhepp | CEO | Sale plan | 14,058 | $22.77 | $320K | Form 4 |
| Aug 10, 2026 | Ivan Hyep | CFO | Sale plan | 12,500 | $27.97 | $350K | Form 4 |
| Aug 10, 2026 | Claire Mazumdar | CEO | Sale plan | 10,000 | $27.98 | $280K | Form 4 |
| Aug 10, 2026 | Ryan Cohlhepp | President | Sale plan | 18,750 | $27.98 | $525K | Form 4 |
| Jul 10, 2026 | Claire Mazumdar | CEO | Sale plan | 9,972 | $28.42 | $283K | Form 4 |
| Jul 10, 2026 | Claire Mazumdar | CEO | Sale plan | 28 | $29.68 | $831 | Form 4 |
| Jul 9, 2026 | Ryan Cohlhepp | President | Sale plan | 536 | $29.00 | $15.5K | Form 4 |
| Jul 8, 2026 | Ryan Cohlhepp | President | Sale plan | 22,833 | $28.76 | $657K | Form 4 |
| Jul 8, 2026 | Ryan Cohlhepp | President | Sale plan | 1,075 | $30.35 | $32.6K | Form 4 |
| Jul 8, 2026 | Ryan Cohlhepp | President | Sale plan | 4,306 | $29.80 | $128K | Form 4 |
| Jul 8, 2026 | Ivan Hyep | CFO | Sale plan | 830 | $30.31 | $25.2K | Form 4 |
| Jul 8, 2026 | Ivan Hyep | CFO | Sale plan | 22,757 | $28.60 | $651K | Form 4 |
| Jul 8, 2026 | Ivan Hyep | CFO | Sale plan | 4,413 | $29.82 | $132K | Form 4 |
| May 21, 2026 | Ivan Hyep | CFO | Sale plan | 9,200 | $20.42 | $188K | Form 4 |
| May 18, 2026 | Claire Mazumdar | CEO | Sale plan | 12,022 | $19.96 | $240K | Form 4 |
| May 18, 2026 | Claire Mazumdar | CEO | Sale plan | 2,978 | $20.35 | $60.6K | Form 4 |
| May 15, 2026 | Ryan Cohlhepp | President | Sale plan | 8,000 | $20.29 | $162K | Form 4 |
| May 15, 2026 | Ryan Cohlhepp | President | Sale plan | 4,500 | $20.29 | $91.3K | Form 4 |
| Apr 27, 2026 | David Raben | Chief Medical Officer | Sale plan | 5,500 | $22.88 | $126K | Form 4 |
| Apr 21, 2026 | Ivan Hyep | CFO | Sale plan | 9,200 | $23.00 | $212K | Form 4 |
| Apr 20, 2026 | Claire Mazumdar | CEO | Sale plan | 15,000 | $23.61 | $354K | Form 4 |
| Apr 15, 2026 | Ryan Cohlhepp | President | Sale plan | 4,500 | $23.01 | $104K | Form 4 |
| Apr 15, 2026 | Ryan Cohlhepp | President | Sale plan | 8,000 | $23.01 | $184K | Form 4 |
| Mar 25, 2026 | David Raben | Chief Medical Officer | Sale plan | 5,500 | $18.95 | $104K | Form 4 |
| Mar 23, 2026 | Ivan Hyep | CFO | Sale plan | 9,200 | $18.52 | $170K | Form 4 |
| Mar 20, 2026 | Claire Mazumdar | CEO | Sale plan | 1,596 | $18.95 | $30.2K | Form 4 |
| Mar 19, 2026 | Claire Mazumdar | CEO | Sale plan | 6,905 | $18.78 | $130K | Form 4 |
| Mar 18, 2026 | Claire Mazumdar | CEO | Sale plan | 6,499 | $18.84 | $122K | Form 4 |
| Mar 16, 2026 | Ryan Cohlhepp | President | Sale plan | 8,000 | $19.66 | $157K | Form 4 |
| Mar 16, 2026 | Ryan Cohlhepp | President | Sale plan | 4,500 | $19.66 | $88.5K | Form 4 |
| Mar 9, 2026 | Claire Mazumdar | CEO | Sale plan | 36,766 | $19.17 | $705K | Form 4 |
| Mar 6, 2026 | Claire Mazumdar | CEO | Sale plan | 3,817 | $18.75 | $71.6K | Form 4 |
| Mar 5, 2026 | Claire Mazumdar | CEO | Sale plan | 1,786 | $18.74 | $33.5K | Form 4 |
| Mar 4, 2026 | Claire Mazumdar | CEO | Sale plan | 2,631 | $18.73 | $49.3K | Form 4 |
| Mar 4, 2026 | Ivan Hyep | CFO | Sale plan | 2,963 | $18.25 | $54.1K | Form 4 |
| Mar 4, 2026 | David Raben | Chief Medical Officer | Sale plan | 16,300 | $18.52 | $302K | Form 4 |
| Mar 3, 2026 | Ryan Cohlhepp | President | Sale plan | 12,892 | $18.16 | $234K | Form 4 |
| Mar 3, 2026 | Ryan Cohlhepp | President | Sale plan | 4,500 | $18.16 | $81.7K | Form 4 |
| Mar 3, 2026 | Ivan Hyep | CFO | Sale plan | 13,555 | $18.22 | $247K | Form 4 |
| Mar 3, 2026 | David Raben | Chief Medical Officer | Sale plan | 200 | $18.45 | $3.7K | Form 4 |
| Feb 26, 2026 | Ra Capital Management, L.P. +4 | Director | Purchase | 300,000 | $16.00 | $4.8M | Form 4 |
| Feb 25, 2026 | Ryan Cohlhepp | President | Sale plan | 3,108 | $18.04 | $56.1K | Form 4 |
| Feb 25, 2026 | Ryan Cohlhepp | President | Sale plan | 523 | $18.04 | $9.4K | Form 4 |
| Jan 22, 2026 | Ryan Cohlhepp | President | Sale plan | 3,828 | $18.10 | $69.3K | Form 4 |
| Jan 22, 2026 | Ivan Hyep | CFO | Sale plan | 1,882 | $18.15 | $34.2K | Form 4 |
| Jan 15, 2026 | Ryan Cohlhepp | President | Sale plan | 149 | $18.02 | $2.7K | Form 4 |
| Dec 22, 2025 | Ivan Hyep | CFO | Sale plan | 9,200 | $18.31 | $168K | Form 4 |
| Dec 15, 2025 | Ryan Cohlhepp | President | Sale plan | 4,500 | $18.68 | $84.1K | Form 4 |
| Dec 15, 2025 | Ryan Cohlhepp | President | Sale plan | 8,000 | $18.68 | $149K | Form 4 |
| Nov 25, 2025 | David Raben | Chief Medical Officer | Sale plan | 906 | $18.84 | $17.1K | Form 4 |
| Nov 25, 2025 | David Raben | Chief Medical Officer | Sale plan | 4,594 | $18.84 | $86.6K | Form 4 |
| Nov 24, 2025 | Ivan Hyep | CFO | Sale plan | 17,795 | $18.55 | $330K | Form 4 |
| Nov 24, 2025 | Claire Mazumdar | CEO | Sale plan | 41,163 | $18.86 | $776K | Form 4 |
| Nov 24, 2025 | David Raben | Chief Medical Officer | Sale plan | 5,500 | $18.45 | $101K | Form 4 |
| Nov 21, 2025 | Ivan Hyep | CFO | Sale plan | 605 | $18.15 | $11K | Form 4 |
| Nov 21, 2025 | Ryan Cohlhepp | President | Sale plan | 4,500 | $18.05 | $81.2K | Form 4 |
| Nov 21, 2025 | Ryan Cohlhepp | President | Sale plan | 8,000 | $18.05 | $144K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Ra Capital Management, L.P. | Director, 10% owner | $4.8M | – | Feb 26, 2026 |
| Ryan Cohlhepp | President and COO, Director | – | $3.5M | Sep 8, 2026 |
| Claire Mazumdar | Chief Executive Officer, Director | – | $3.1M | Aug 10, 2026 |
| Ivan Hyep | Chief Financial Officer | – | $2.6M | Aug 10, 2026 |
| David Raben | Chief Medical Officer | – | $741K | Apr 27, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
BCAX short interest
High short interest. 14.9% of BCAX shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short barely changed.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 9.86M BCAX shares were sold short, 14.9% of the shares outstanding, down 4.2% from the report before. At the average daily volume of 2.57M shares, buying them all back would take about 3.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 9.86M | 14.90% | -4% | 2.57M | 3.8 |
| Oct 15, 2026 | 10.30M | 15.56% | -4% | 893,322 | 11.5 |
| Sep 30, 2026 | 10.69M | 16.16% | -4% | 753,208 | 14.2 |
| Sep 15, 2026 | 11.19M | 16.91% | +3% | 496,027 | 22.6 |
| Aug 31, 2026 | 10.85M | 16.39% | +4% | 491,104 | 22.1 |
| Aug 14, 2026 | 10.46M | 15.81% | +9% | 787,826 | 13.3 |
| Jul 31, 2026 | 9.60M | 14.66% | +3% | 469,965 | 20.4 |
| Jul 15, 2026 | 9.32M | 14.23% | -8% | 734,248 | 12.7 |
| Jun 30, 2026 | 10.12M | 15.46% | -0% | 1.38M | 7.3 |
| Jun 15, 2026 | 10.16M | 15.52% | +1% | 514,104 | 19.8 |
| May 29, 2026 | 10.08M | 15.40% | +2% | 448,419 | 22.5 |
| May 15, 2026 | 9.85M | 15.04% | +11% | 568,908 | 17.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Bicara Therapeutics company events
Bicara Therapeutics filed 12 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Aug 25, 2026AgreementBicara Therapeutics Inc. entered into a Sub-Sublease Agreement with Wayfair LLC, as sublandlord, pursuant to which the Company, as subtenant, will lease approximately 35,090 square feet of office space for new corporate headquarters to be located at 10 St. James Avenue, Boston, Massachusetts 02116. Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Jul 28, 2026LeadershipKiran Mazumdar-Shaw resigned from the Board of Directors of Bicara Therapeutics Inc. and her position on the Nominating and Corporate Governance Committee of the Board, effective as of July 28, 2026. Filing
- Jun 10, 2026VoteReported shareholder vote results. Filing
- May 21, 2026AnnouncementBicara Therapeutics Inc. issued a press release entitled “Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC.” A copy of the press release is attached hereto as Exhibit 99.1 and is… Filing
- May 11, 2026ResultsReleased financial results. Filing
- Mar 30, 2026ResultsReleased financial results. Filing
- Feb 26, 2026AgreementBicara Therapeutics Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives of the underwriters named therein, pursuant to which the Company agreed to issue and sell an aggregate of (i) 7,175,000 shares of its… Filing
- Feb 19, 2026AnnouncementBicara Therapeutics Inc. issued a press release entitled “Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein… Filing
- Jan 12, 2026AnnouncementBicara Therapeutics Inc. issued a press release entitled “Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Filing
- Dec 8, 2025AnnouncementThe Company announced preliminary data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa weekly in combination with pembrolizumab in first-line human papillomavirus-negative recurrent/metastatic head and neck squamous cell carcinoma. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Bicara Therapeutics financials
Famous investors that hold BCAX
4 of the 50 well-known investors we track reported holding BCAX in their latest 13F filing. The largest position is Ken Griffin's, worth $19.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.03M | $19.2M | 0.0% | +388% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 627,108 | $11.7M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 591,022 | $11M | 0.0% | +125% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 33,086 | $616K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named BCAX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 7, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 4.2% |
| Oct 7, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 4.2% |
Questions about Bicara Therapeutics Inc. (BCAX) stock
Who owns the most BCAX stock?
The largest reported owner of Bicara Therapeutics Inc. (BCAX) is Ra Capital Management, L.P., with 11.1% of the company. In total, 172 funds and institutions reported holding BCAX at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are BCAX insiders buying or selling?
In the last 12 months, BCAX insiders reported 1 open-market purchase worth $4.8M and 57 sales worth $9.9M. The latest trade was on Sep 8, 2026. See every trade.
What is the short interest in BCAX?
As of Oct 30, 2026, 9.86M BCAX shares were sold short, 14.9% of the shares outstanding, down 4.2% from the report before. At the average daily volume of 2.57M shares, buying them all back would take about 3.8 trading days (days to cover). See the history.
Which famous investors hold BCAX?
4 of the 50 well-known investors we track reported BCAX in their latest 13F filing, including Ken Griffin, Steve Cohen, Israel Englander. The largest position is worth $19.2M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.